Pionyr Immunotherapeutics, Inc. was acquired by Ikena Oncology, Inc. in August 2023

August 07, 2023 Press Release    Visit ikenaoncology.com

Pionyr Pipeline

Pionyr’s Myeloid Tuning™ programs are designed to enhance the immune system’s anti-tumor response by specifically altering the cellular infiltrate of the tumor microenvironment. Pionyr’s clinical programs, PY314 and PY159, targeting TREM2 and TREM1 respectively, are designed to selectively deplete and, in some cases, reprogram certain tumor-associated macrophages responsible for immunosuppression. PY314 and PY159 have demonstrated safety alone and in combination with pembrolizumab in Phase 1a/b trials. Pionyr’s third program, PY265 (anti-MARCO) is IND-ready.

Program (Target)
PY314 (TREM2) / Depletion
PY159 (TREM1) / Repolarization
PY265 (MARCO) / Immune Activation
TME Targeting

Posters & Publications

Posters, Publications and whitepapers from Pionyr Immunotherapeutics

View Posters & Publications

Business Development

Ikena’s business development team is open to discussion regarding licensing and other partnerships for the Pionyr programs. Please contact bd@ikenaoncology.com for more information.